All In Biotech

Drug Trial Radar · NCT07913360

GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer

A Multicenter, Open-label, Randomized Controlled Phase III Study Evaluating the Efficacy and Safety/Tolerability of GFH375 in Combination With Cetuximab Versus Investigator's Choice of Treatment in Patients With KRAS G12D Mutant Metastatic Colorectal Cancer Refractory to Oxaliplatin, Fluoropyrimidines, and Irinotecan

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

368

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion May 2030

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).

Conditions

  • Colorectal Cancer

Interventions

  • GFH375 + CetuximabDrug

    GFH375:600 mg orally, once daily Cetuximab :500 mg/m² intravenously every 2 weeks

  • FruquintinibDrug

    35 mg/m² orally twice daily (max single dose 80 mg) on Days 1-5 and Days 8-12

  • Trifluridine and TipiracilDrug

    5 mg orally once daily on Days 1-21

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to approximately 2 years
  2. Overall survival(OS)Time frame: Up to approximately three and a half years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.